Iovance Biotherapeutics, Inc. Announces Executive Changes
June 13, 2020 at 02:47 am IST
Share
On June 12, 2020, Iovance Biotherapeutics, Inc. announced Michael C. Swartzburg, the company’s Vice President, Finance, was appointed to replace Mr. Timothy Morris as the company’s Principal Accounting Officer, Effective as of June 10, 2020,. Mr. Swartzburg has served as the company’s Vice President, Finance since March 2018. From June 2014 to August 2016, Mr. Swartzburg served in roles at Adverum Biotechnolgies, Inc., including serving as Vice President, Finance, Controller, and Principal Accounting Officer.
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.